## Shih-Jen Liu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6575968/publications.pdf

Version: 2024-02-01

186265 214800 2,580 91 28 47 citations h-index g-index papers 91 91 91 3534 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity. International Journal of Molecular Sciences, 2022, 23, 4902.	4.1	9
2	A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. Npj Vaccines, 2022, 7, .	6.0	21
3	Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy. Journal of Biomedical Science, 2022, 29, .	7.0	4
4	DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss. PLoS Neglected Tropical Diseases, 2021, 15, e0009374.	3.0	18
5	A Novel Recombinant $Fc\hat{l}^3$ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment. Biomedicines, 2021, 9, 806.	3.2	5
6	Characterization of Virus Replication, Pathogenesis, and Cytokine Responses in Syrian Hamsters Inoculated with SARS-CoV-2. Journal of Inflammation Research, 2021, Volume 14, 3781-3795.	3.5	13
7	Squalene nanoemulsion reinforces mucosal and immunological fingerprints following intravaginal delivery. Biomedicine and Pharmacotherapy, 2021, 141, 111799.	5.6	7
8	Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19. International Journal of Pharmaceutics, 2021, 607, 121024.	5.2	9
9	Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment., 2021, 9, e002758.		7
10	Intranasal Vaccination With Recombinant Antigen-FLIPr Fusion Protein Alone Induces Long-Lasting Systemic Antibody Responses and Broad T Cell Responses. Frontiers in Immunology, 2021, 12, 751883.	4.8	5
11	Nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination., 2020, 8, e001022.		13
12	A Polypeptide of Tumor-Associated Antigen L6 with Intrinsic Adjuvant Activity Enhances Antitumor Immunity. Vaccines, 2020, 8, 620.	4.4	1
13	Liposomal TLR9 Agonist Combined with TLR2 Agonist-Fused Antigen Can Modulate Tumor Microenvironment through Dendritic Cells. Cancers, 2020, 12, 810.	3.7	10
14	Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice. Journal of Biomedical Science, 2020, 27, 51.	7.0	6
15	Domain 4 of pneumolysin from Streptococcus pneumoniae is a multifunctional domain contributing TLR4 activating and hemolytic activity. Biochemical and Biophysical Research Communications, 2019, 517, 596-602.	2.1	7
16	Delivery of Antigen to CD8+ Dendritic Cells by Fusing Antigen With Formyl Peptide Receptor-Like 1 Inhibitor Protein Induces Antitumor Immunity. Frontiers in Immunology, 2019, 10, 1839.	4.8	10
17	Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy. Vaccine: X, 2019, 1, 100017.	2.1	14
18	Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine. American Journal of Cancer Research, 2019, 9, 2028-2036.	1.4	5

#	Article	IF	CITATIONS
19	Polysorbasome: A Colloidal Vesicle Contoured by Polymeric Bioresorbable Amphiphiles as an Immunogenic Depot for Vaccine Delivery. ACS Applied Materials & Samp; Interfaces, 2018, 10, 12553-12561.	8.0	10
20	Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity. Frontiers in Immunology, 2018, 9, 822.	4.8	7
21	Infection with the dengue RNA virus activates TLR9 signaling in human dendritic cells. EMBO Reports, 2018, 19, .	4.5	74
22	A therapeutic vaccine targeting HPV E6/E7 with intrinsic Toll-like receptor 2 agonist activity induces antitumor immunity. American Journal of Cancer Research, 2018, 8, 2528-2537.	1.4	4
23	Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy, 2017, 9, 347-360.	2.0	154
24	CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses. Scientific Reports, 2017, 7, 17297.	3.3	21
25	A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population. Oncotarget, 2016, 7, 30804-30819.	1.8	14
26	Carboxyl-terminal fusion of E7 into Flagellin shifts TLR5 activation to NLRC4/NAIP5 activation and induces TLR5-independent anti-tumor immunity. Scientific Reports, 2016, 6, 24199.	3.3	14
27	Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice. Scientific Reports, 2016, 6, 30648.	3.3	32
28	Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice. Cancer Letters, 2016, 377, 126-133.	7.2	13
29	A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity. Journal of Controlled Release, 2016, 233, 57-63.	9.9	16
30	Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy. Scientific Reports, 2016, 6, 36732.	3.3	14
31	Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. Vaccine, 2016, 34, 1054-1061.	3.8	19
32	Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy. Oncolmmunology, 2016, 5, e1095433.	4.6	15
33	Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget, 2016, 7, 85917-85928.	1.8	6
34	A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model. Oncotarget, 2016, 7, 671-683.	1.8	7
35	A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Scientific Reports, 2015, 5, 12578.	3.3	28
36	Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact. Expert Review of Vaccines, 2015, 14, 383-394.	4.4	11

#	Article	IF	CITATIONS
37	Recombinant Lipoproteins as Novel Vaccines with Intrinsic Adjuvant. Advances in Protein Chemistry and Structural Biology, 2015, 99, 55-74.	2.3	8
38	Recombinant bacterial lipoproteins as vaccine candidates. Expert Review of Vaccines, 2015, 14, 1623-1632.	4.4	17
39	Recombinant lipoprotein-based vaccine candidates against C. difficile infections. Journal of Biomedical Science, 2015, 22, 65.	<b>7.</b> O	13
40	Toll-Like Receptor 9-Mediated Protection of Enterovirus 71 Infection in Mice Is Due to the Release of Danger-Associated Molecular Patterns. Journal of Virology, 2014, 88, 11658-11670.	3.4	35
41	Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide. Human Vaccines and Immunotherapeutics, 2014, 10, 3241-3250.	3.3	22
42	Molecular Mechanisms of TLR2-Mediated Antigen Cross-Presentation in Dendritic Cells. Journal of Immunology, 2014, 192, 4233-4241.	0.8	40
43	Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems. BioMed Research International, 2014, 2014, 1-8.	1.9	16
44	A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy. BioMed Research International, 2014, 2014, 1-10.	1.9	5
45	Delivery of Human EV71 Receptors by Adeno-Associated Virus Increases EV71 Infection-Induced Local Inflammation in Adult Mice. BioMed Research International, 2014, 2014, 1-12.	1.9	2
46	Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine, 2014, 32, 1346-1353.	3.8	32
47	Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Molecular Cancer, 2014, 13, 60.	19.2	40
48	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-polylactide. Biomaterials, 2014, 35, 1686-1695.	11.4	27
49	A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. Journal of Controlled Release, 2014, 173, 158-165.	9.9	44
50	A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Archives of Virology, 2013, 158, 1523-1531.	2.1	45
51	Mesenchymal Stem Cells Tune the Development of Monocyte-Derived Dendritic Cells Toward a Myeloid-Derived Suppressive Phenotype through Growth-Regulated Oncogene Chemokines. Journal of Immunology, 2013, 190, 5065-5077.	0.8	92
52	Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III. Microbes and Infection, 2013, 15, 719-728.	1.9	14
53	Enzymatic Stability and Immunoregulatory Efficacy of a Synthetic Indolicidin Analogue with Regular Enantiomeric Sequence. ACS Medicinal Chemistry Letters, 2013, 4, 522-526.	2.8	6
54	Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement. PLoS Neglected Tropical Diseases, 2013, 7, e2432.	3.0	34

#	Article	IF	Citations
55	Production of EV71 vaccine candidates. Human Vaccines and Immunotherapeutics, 2012, 8, 1775-1783.	3.3	64
56	Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	29
57	Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy. Frontiers in Oncology, 2012, 2, 149.	2.8	7
58	CD4+ T Cells Disarm or Delete Cytotoxic T Lymphocytes under IL-17–Polarizing Conditions. Journal of Immunology, 2012, 189, 1671-1679.	0.8	18
59	A Novel HLA-A2–restricted CTL Epitope of Tumor-associated Antigen L6 can Inhibit Tumor Growth In Vivo. Journal of Immunotherapy, 2012, 35, 235-244.	2.4	17
60	Dengue-1 Envelope Protein Domain III along with PELC and CpG Oligodeoxynucleotides Synergistically Enhances Immune Responses. PLoS Neglected Tropical Diseases, 2012, 6, e1645.	3.0	29
61	Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. International Journal of Nanomedicine, 2012, 7, 607.	6.7	18
62	Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model. PLoS ONE, 2012, 7, e40970.	2.5	42
63	Increased expression of IL-21 reduces tumor growth by modulating the status of tumor-infiltrated lymphocytes. Immunobiology, 2011, 216, 491-496.	1.9	8
64	Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine, 2011, 29, 4362-4372.	3.8	158
65	Rapid and sensitive detection of cancer cells by coupling with quantum dots and immunomagnetic separation at low concentrations. Biosensors and Bioelectronics, 2011, 26, 4249-4252.	10.1	26
66	Tâ€cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. Journal of Medical Virology, 2011, 83, 1023-1030.	5.0	8
67	Presentation of lipopeptide by dendritic cells induces anti-tumor responses via an endocytosis-independent pathway in vivo. Journal of Leukocyte Biology, 2011, 90, 323-332.	3.3	26
68	Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer. Molecular Cancer Therapeutics, 2011, 10, 637-647.	4.1	14
69	A Novel Single-Dose Dengue Subunit Vaccine Induces Memory Immune Responses. PLoS ONE, 2011, 6, e23319.	2.5	45
70	Highly sensitive rare cell detection based on quantum dot probe fluorescence analysis. Analytical and Bioanalytical Chemistry, 2010, 396, 1135-1141.	3.7	11
71	Emulsified Nanoparticles Containing Inactivated Influenza Virus and CpG Oligodeoxynucleotides Critically Influences the Host Immune Responses in Mice. PLoS ONE, 2010, 5, e12279.	2.5	37
72	T-Cell Response to Human Papillomavirus Type 58 L1, E6, and E7 Peptides in Women with Cleared Infection, Cervical Intraepithelial Neoplasia, or Invasive Cancer. Vaccine Journal, 2010, 17, 1315-1321.	3.1	7

#	Article	IF	CITATIONS
<b>7</b> 3	Identifying Conserved DR1501-Restricted CD4+T-Cell Epitopes in Avian H5N1 Hemagglutinin Proteins. Viral Immunology, 2010, 23, 585-593.	1.3	3
74	A recombinant lipoprotein containing an unsaturated fatty acid activates NF- $\hat{\mathbb{I}}^2$ B through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Molecular Immunology, 2010, 47, 2015-2021.	2.2	46
<b>7</b> 5	IL-6-transfected tumor cells modulate the status of CD8+ and CD4+ T cells to control tumor growth. Immunobiology, 2010, 215, 486-491.	1.9	6
76	Biochemical characterizations of Escherichia coli-expressed protective antigen Ag473 of Neisseria meningitides group B. Vaccine, 2010, 28, 8175-8182.	3.8	10
77	Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Cancer Biology and Therapy, 2009, 8, 2025-2032.	3.4	14
78	Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)â€∢i>block⟨ i>â€poly(lactideâ€∢i>co⟨ i>â€∢i>ε⟨ i>â€caprolactone). Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2009, 90B, 832-841.	3.4	22
79	Development of Multi-Phase Emulsions Based on Bioresorbable Polymers and Oily Adjuvant. Pharmaceutical Research, 2009, 26, 1856-1862.	3.5	19
80	Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes and Infection, 2009, 11, 654-660.	1.9	17
81	A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes and Infection, 2009, $11$ , 288-295.	1.9	94
82	Immunological study of HA1 domain of hemagglutinin of influenza H5N1 virus. Biochemical and Biophysical Research Communications, 2009, 383, 27-31.	2.1	41
83	Generating and characterizing monoclonal and polyclonal antibodies against avian H5N1 hemagglutinin protein. Biochemical and Biophysical Research Communications, 2009, 382, 691-696.	2.1	22
84	A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine, 2009, 27, 1400-1409.	3.8	66
85	DC-SIGN mediates avian H5N1 influenza virus infection in cis and in trans. Biochemical and Biophysical Research Communications, 2008, 373, 561-566.	2.1	75
86	Induction of a distinct CD8 Tnc17 subset by transforming growth factor- $\hat{l}^2$ and interleukin-6. Journal of Leukocyte Biology, 2007, 82, 354-360.	3.3	106
87	Identification of synthetic vaccine candidates against SARS CoV infection. Biochemical and Biophysical Research Communications, 2007, 358, 716-721.	2.1	16
88	The Development and Application of HLA Tetramers in the Detection, Characterization and Therapy of Type 1 Diabetes Mellitus. Review of Diabetic Studies, 2007, 4, 56-56.	1.3	3
89	Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine, 2006, 24, 3100-3108.	3.8	107
90	Identifying Epitopes Responsible for Neutralizing Antibody and DC-SIGN Binding on the Spike Glycoprotein of the Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2006, 80, 10315-10324.	3.4	45

## SHIH-JEN LIU

#	Article	IF	CITATIONS
91	Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma. Journal of Immunotherapy, 2005, 28, 129-135.	2.4	189